NeoGenomics’ Solid Tumor Test Gets New York State Approval
NeoGenomics received conditional approval from the New York State Department of Health for its Neo Comprehensive Solid Tumor and NeoTYPE DNA & RNA Lung assays.
Read MorePosted by Andy Lundin | Oct 22, 2024 | Lung Cancer, Molecular Diagnostics |
NeoGenomics received conditional approval from the New York State Department of Health for its Neo Comprehensive Solid Tumor and NeoTYPE DNA & RNA Lung assays.
Read MorePosted by Andy Lundin | Oct 22, 2024 | Molecular Diagnostics, Swabs |
OralDNA Labs acquired Sensible Diagnostics to enhance its rapid point-of-care molecular diagnostic testing capabilities.
Read MorePosted by Andy Lundin | Oct 21, 2024 | Womens Health |
A blood test measuring the fibrinogen-to-albumin ratio can predict the risk of preeclampsia in laboring women, improving maternal outcomes.
Read MorePosted by Andy Lundin | Oct 21, 2024 | Unknown Origin & Other Cancer Types |
Thermo Fisher’s CDx for identifying glioma patients eligible for treatment with Servier Pharmaceuticals’ VORANIGO gets FDA approval.
Read MorePosted by Andy Lundin | Oct 16, 2024 | Diagnostic Technologies, POC Instruments |
A handheld, sound-based diagnostic system can deliver precise blood test results in under 70 minutes from a finger prick.
Read More